INTAN AYU PRADIPTA, 050911189 (2013) STUDI PENGGUNAAN ANTIHIPERLIPIDEMIA PADA PASIEN DIABETES NEFROPATI (Penelitian dilakukan di Poli Diabetes dan Ginjal Instalasi Rawat Jalan RSUD Dr. Soetomo Surabaya). Skripsi thesis, UNIVERSITAS AIRLANGGA.

Preview	Text (ABSTRAK) gdlhub-gdl-s1-2014-pradiptain-29524-5.abstr-t.pdf Download (120kB) | Preview
	Text (FULLTEXT) gdlhub-gdl-s1-2014-pradiptain-29524-1.FULLTEXT.pdf Restricted to Registered users only Download (2MB) | Request a copy

Abstract

Patients with diabetic nephropathy frequently have dyslipidemia, associated with insulin resistance and microalbuminuria, thus plasma lipoprotein profiles become more atherogenic compared with diabetics without nephropathy. It may contribute to the increased risk of death from CVD and induces both glomerular and tubulointerstitial injury. Consequently it is important to control lipid plasma with lipid lowering agents while it may contribute to the presence of rhabdomyolisis that affect renal function. Concomitant use of drugs may cause many drug interaction with lipid lowering agents. The aim of this study was to analyze therapy profile of utilization of lipid lowering agents in diabetic nephropathy patients at Diabetic and Kidney Clinic Dr. Soetomo Surabaya from 7th March to 7th June 2013. The study was observational with cross sectional method. The result showed that from 108 patient, dyslipidemia was more prevalence in women (61,11%) than men (38,89%) while the age range of most patients were in group of 40-65 years (75,00%). Patients were in stage ND III, IV and V, who had microalbuminuria (40,68%) and macroalbuminuria (37,29%). CVD was the highest complication-comorbid (14,81%). Type of lipid lowering agents were simvastatin 10 - 20 mg (96,29%), atorvastatin 20 mg (0,93%), gemfibrozil 300 mg (3,70%) and fenofibrat 100 mg (2,78%), used in monotherapy (96,30%) and combination (2,70%). The incidence of DRPs (one patients may experienced more than one DRP) were inappropriate drug of choice (15,38%), inappropriate dose (6,48%),and drug interaction (4,63%). In conclusion, lipid lowering agents used in this study were simvastatin 10-20 mg, atorvastatin 20 mg, gemfibrozil 300 mg and fenofibrat 100 mg, used in monotherapy and combination. The incidence of DRPs were inappropriate drug of choice, dose and drug interaction.

Actions (login required)

View Item